Agilus Diagnostics has launched an automated molecular diagnostics platform capable of detecting key cancer-related genetic mutations within 2.5 to 3 hours, reducing the time required for biomarker testing. The rapid testing capability is expected to support faster treatment decisions and improve access to precision oncology and targeted cancer therapies.